The biotech company continues to offer hope to systemic lupus erythematosus (SLE) patients globally by sharing the latest developments of its proprietary novel fusion protein drug Telitacicept YANTAI, China, May 10, 2024 /PRNewswire/ — RemeGen Co. Ltd. (“RemeGen” or “the Company”)…